25 January 2022 – Congratulations to Neurelis on their recent licensing agreement with Aculys Pharma for the development and commercialization of VALTOCO® in Japan and the Asia-Pacific Region. PLC has supported the clinical development and regulatory pathway of VALTOCO from inception and continues to provide clinical oversight of ongoing trials and regulatory support for Neurelis and their continuing drug product development in the US.
NEURELIS SIGNS EXCLUSIVE LICENSING AGREEMENT WITH ACULYS PHARMA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN JAPAN AND THE ASIA-PACIFIC REGION
